Takeda Warns New Drugs at Risk If Countries Push Deep Price Cuts Pressure to reduce medicine prices swirls in US, Europe ‘You cannot just close the eyes and squeeze the price’: Weber ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on Friday at the TD Garden.

For Takeda, LinkedIn is very much a work in progress, particularly when it comes to melding together the corporate content and recruitment objectives. “We’re taking a very data-led approach to ...

Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments ...

“At Takeda, we set out on a journey to build a best-in-class global communications organization, empowered by a team of exceptional professionals who I truly see as business leaders,” Belo said on ...

BlueSky linkedin youtube rss. ... Takeda could acquire next-generation immunotherapies as it seeks to broaden its offering in the hyper-competitive field of cancer treatment.

Takeda’s drug could more clearly distinguish itself from Sotyktu at 30 mg, the highest of the four doses tested, Phipps said. This dose has the potential for higher rates of patients achieving ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin ...

Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that a former employee took trade secrets with him to his new job at the rival drugmaker.

Takeda announced the results Saturday morning and will present them at a medical conference for dermatologists in New Orleans over the weekend. STAT+ Exclusive Story. Already have an account?

Bhambi joined Takeda in November 2017 after four years at Cambridge-based Biogen, according to her LinkedIn page. She ultimately rose to chief of staff of global data and technology, the company said.

Takeda will consider selling businesses from its . Nycomed acquisition in 2011, as Japan’s largest pharmaceutical group seeks to divest $10bn of assets after completing a £46bn deal to buy Shire.